Combined counseling and bupropion therapy for smoking cessation: Identification of outcome predictors

Drug Development Research

Volumn 67, Issue 3, 2006, Pages 271-279

  Grassi, Maria Caterina ^a   Enea, Domenico ^a   Marchetti, Rosanna ^a   Caricati, Alessio Maria ^a   Nencini, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bupropion; Nicotine dependence; Predictors of outcome; SDS; Smoking cessation

Indexed keywords

AMFEBUTAMONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FAGESTROM TOLERANCE QUESTIONNAIRE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; RATING SCALE; SEVERITY OF DEPENDENCE SCALE; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

EID: 33746256066     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20085     Document Type: Article

References (59)

1. Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Majo MS. 2000. Sustained-release bupropion for smoking cessation in African Americans. A randomized controlled trial. JAMA 288:497-499.
2. American Psychiatric Association. 1997. Diagnostic and Statistical Manual of Mental Disorders. DSM-IV. APS, Washington DC. p 181-183.
3. Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G. 2004. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. Addiction 99:1206-1218.
4. Bombard J, Malarcher A, Schooley M, MacNeil A. 2004. State-specific prevalence of current cigarette smoking among adults-United States, 2003. JAMA 292:2966-2967.
5. Chatkin JM, Mariante de Abreu C, Haggstram FM, Wagner MB, Fritscher CC. 2004. Abstinence rates and predictors of outcome for smoking cessation: do Brazilian smokers need special strategies? Addiction 99:778-784.
6. Cousins MS, Stamat HM, De Wit H. 2001. Acute dose of d-amphetamine and bupropion increase cigarette smoking. Psychopharmacology 157:243-253.
7. Cowling DW, Johnson TP, Holbrook BC, Warnecke RB, Tang H. 2003. Improving the self reporting of tobacco use: results of a factorial experiment. Tob Control 12:178-183.
8. Dale LC, Glover ED, Sachs DP, Schroeder DR, Offord KP, Croghan IT, Hurt RD. 2001. Bupropion for smoking cessation: predictors of successful outcome. Chest 119:1357-1364.
9. de las Cuevas C, Sanz EJ, de la Fuente JA, Padilla J, Berenguer JC. 2000. The Severity of Dependence Scale (SDS) as screening test for benzodiazepine dependence: SDS validation study. Addiction 95:245-250.
10. Etter JF. 2005. A comparison of the content- construct- and predictive validity of the cigarette dependence scale and the Fageström test for nicotine dependence. Drug Alcohol Depend 77:259-268.
11. Fageström KO. 1978. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 3:235-341.
12. Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER, Heyman RB, Jaén CR, Kottke TE, Lando HA, Mecklenburg R, Mullen PD, Nett LM, Robinson K, Stitzer ML, Tommasello AC, Villejo L, Wewers ME. 2000. Treating tobacco use and dependence. Rockville MD: US Department of Health and Human Services, Clinical Practice Guideline Public Health Service (http://www. surgeongeneral.gov/tobacco).
13. Frikart M, Etienne S, Cornuz J, Zellweger JP. 2003. Five-day plan for smoking cessation using group behaviour therapy. Swiss Med Wkly 133:39-43.
14. Gallus S, Colombo P, Scarpino V, Zuccaro P, Apolone G, La Vecchia C. 2002. Smoking in Italy, 2002. Tumori 88:453-456.
15. Gallus S, Colombo P, Scarpino V, Zuccaro P, Basetti C, Apolone G, La Vecchia C. 2004. Smoking in Italy 2003, with a focus on the young. Tumori 90:171-174.
16. Gariti P, Alterman AI, Ehrman R, Mulvaney FD, O'Brien CP. 2002. Detecting smoking following smoking cessation treatment. Drug and Alcohol Depend 65:191-196.
17. Gossop M, Darke S, Griffith P, Hando J, Powis B, Hall W, Strang J. 1995. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90:607-614.
18. Gossop M, Best D, Marsden J, Strang J. 1997. Test-retest reliability of the severity of dependence scale. Addiction 92:353-354.
19. Grassi MC, Pisetzky F, Nencini P. 2000. L'approccio tossicologico alia clinica delle tossicodipendenze: scelta ragionata delle scale di intensità della dipendenza. Ann 1st Super Sanità 36:9-16.
20. Grassi MC, Bencetti ML, Caricati AM, Nencini P. 2002. Predictive factors of persisting illicit drug use in hospitalized heroin addicts. Pharmacol Res 46:539-544.
21. Guideliness for prevention, Diagnosis and Therapy in Oncology. 2001. Ministry of Health, Regions and self-governing Departments of Trento and Bolzano. Suppl. 102: G.U. n.100, May 2, 2001. Linee guide concernenti la prevenzione la diagnosi e l'assistenza in oncologia. Accordo tra il Ministero della Sanita' e le regioni e province autonome di Trento e Bolzano. 2001. Suppl. 102 GU: n100, 2 maggio 2001.
22. Harris KJ, Okuyemi KS, Catley D, Mayo MS, Ge B, Akluwalia JS. 2004. Predictors of smoking cessation among African-Americans enrolled in a randomized controlled trial of bupropion. Prev Med 38:498-592.
23. Harrison L, Hughes A. 1997. The validity of self-reported drug use: Improving the accuracy of survey estimates. NIDA Res Monogr 167:1-16.
24. Hartz DT, Frederick-Osborne SL, Galloway GP. 2001. Craving predicts use during treatment for methamphetamine dependence: a prospective repeated-measures within-subject analysis. Drug Alcohol Depend 63:269-276.
25. Hays JT, Ebbert JO. 2003a. Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits. Drugs 17:71-83.
26. Hays JT, Ebbert JO, 2003b. Bupropion sustained release for treatment of tobacco dependence. Mayo Clin Proc 78:1020-1024.
27. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, Sachs DP, Wolter TD, Buist AS, Johnston JA, White JD. 2001. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized controlled trial. Ann Intern Med 135:423-433.
28. Hughes JR, Goldstein MG, Hurt RD, Schiffman S. 1999. Recent advances in the pharmacotherapy of smoking. JAMA 281:72-76.
29. Hurt RD, Sachs DPL, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM. 1997. Comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1119-1202.
30. Hurt RD, Wolter TD, Rigotti N, Hays JT, Niaura R, Durcan MJ, Gonzales D, Sachs DP, Johnston JA, Offord KP. 2002. Bupropion for pharmacologic relapse prevention to smoking: predictors of outcome. Addict Behav 27:493-507.
31. Jorenby D. 2002. Clinical efficacy of bupropion in the management of smoking cessation, Drugs 62(Suppl 2):25-35.
32. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto, ML Daughton DM, Doan K, Fiore MC, Baker TB. 1999. A controlled trial of sustained-release bupropion, a nicotine patch or both for smoking cessation. N Engl J Med 340:685-691.
33. Lancaster T, Stead L, Silagy C, Sowden A. 2002. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. BMJ 321:355-358.
34. Mangiaracina G. 2003. Curare il Fumo. Roma. Ed Università Popolare.
35. Max W, Rice DP, Sung HY, Zhang X, Miller L. 2004. The economic burden of smoking in California. Tob Control 13:264-267.
36. Maxwell C. 1978. Sensitivity and accuracy of the visual analogue scale: a psycho-physical classroom experiment. Br J of Clin Pharmacol 6:15-24.
37. McFarland JW, Folkenberg EJ. 1964. How to stop smoking in five days. NJ: Prentice-Hall Inc, Englewood Cliffs.
38. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. 2000. Drug dependence, a chronic medical illness: implications for treatment, insurance and outcomes evaluation. JAMA 284:1689-1695.
39. National Institute of Drug Abuse. 2004. Teen drug use declines 2003-2004. (http://www.drugabuse.gov/NIDAHome.html)
40. Nicholson AN. 1978. Visual Analogue Scales and drug effects in man. Br J Clin Pharmacol 6:3-4.
41. Ortiz A, Martinez M, Torres A, Casal J, Rodriguez W, Nazario S. 2003. Predictors of smoking cessation success. P R Health Sci J 22:173-177.
42. OSSFAD. 2004. Indagine DOXA: il fumo in Italia. (DOXA: Smoking in Italy.) Ist Super Sanità (http://www.iss.it/sitp/ofad/index.html).
43. Patrick DL, Cheadle A, Thompson DC, Diehr P, Koepsell T, Kinne S. 1994. The validity of self-reported smoking: a review and meta-analysis. Am J Public Health 84:1086-1093.
44. Rigotti NA. 2002. Treatment of tobacco use and dependence. N Engl J Med 346:506-512.
45. Rossi S, Carosi G, Mortali C, Mattioli D, Mazzola M, Pacifici R. 2004. Report on smoking in Italy, 1st Super Sanità (http://www.epicentro.iss. it/temi/fumo/dati.htm).
46. Russo R, Scafato E. 2000. Smoking and Health: Social impact and health burden. OSSFAD (www.iss.it/sitp/ofad/publ/ppdf/0003.pdf).
47. Sampablo I, Lores L, Coll-Klein F, Jimenez C, Rebasa P. 2003. Predictive factors in smoking cessation with combined therapy with bupropion and nicotine patches. Monaldi Arch Chest Dis 59:171-176.
48. Schnoll RA, James C, Malstrom M, Rothman RL, Wang H, Babb J, Miller SM, Ridge JA, Movsas B, Langer C, Unger M, Goldberg M. 2003. Longitudinal predictors of continued tobacco use among patients diagnosed with cancer, Annals of Behav Med 25:214-222.
49. Schnoll RA, Rothman RL, Newman H, Lerman C, Miller, SM, Movsas B, Sherman E, Ridge JA, Unger M, Langer C, Goldberg M, Scott W, Cheng J. 2004. Characteristics of cancer patients entering a smoking cessation program and correlates of quit motivation: implications for the development of tobacco control programs for cancer patients. Psychooncology 13:346-358.
50. Sgambato A, Cicchetti A, Papa M, Macinati S, Sposi A, Cittadini A, 2001. Economic and social impact of smoke-related diseases in Italy. Oncological Research Center "Giovanni XXIII", Catholic University of Sacred Heart, Rome. (http://www.epicentro.iss.it/temi/fumo/dati.htm).
51. SPSS for Windows, version 9.0.1. 1989-1999, Chicago, IL.
52. Swan GE, Jack LM, Curry S, Chorost M, Javitz H, McAfee T, Dacey S. 2003. Bupropion SR and counseling for smoking cessation in actual practice: predictors of outcome. Nicotine Tob Res 6:911-921.
53. Thompson DS, Wilson TR. 1966. Discontinuance of cigarette smoking: "natural" and with "therapy". A ten-week and ten-month follow-up study of 298 adult participants in a five-day plan to stop smoking. JAMA 196:1048-1052.
54. Tonnesen P, Tonstad S, Hjalmarson A, Lebargy F, Van Spiegel PI, Hider A, Sweet R, Townsend J. 2003. A multicentre randomized double blind placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med 254:184-192.
55. Topp L, Mattick RP. 1997. Choosing a cut-off on the Severity of Dependence Scale (SDS) for amphetamine users. Addiction 92: 839-845.
56. US Dept of Health and Human Services. 1990. The Health Benefits of Smoking Cessation: A Report of the Surgeon General Atlanta Ga: US Dept of Health and Human Service, Centers for Disease Control and Prevention, Center for Chronic Disease Prevention and Health promotion, office on Smoking and Health. DHHS publication CDC 90-8416.
57. US Public Health Service report. 2000. A clinical practice guideline for treating tobacco use and dependence. JAMA 283:3244-3254.
58. World Health Organization (WHO). 1997. Tobacco or Health: A global Status Report. Geneva: World Health Organization. p 1-32.
59. Zhu SH, Anderson CM, Tedeschi GJ, Rosbrook B, Johnson C, Byrd M, Gutiérrez-Terrell E. 2002. Evidence of real-world effectiveness of a telephone quitline for smokers. N Engl J Med 14:1087-1093.